MONTANA MOLECULAR, LLC
Biotech · Private
Fluorescent live-cell assays for G12/13 G-protein coupled receptor pathway activation, and CRISPR/Cas9 tools for selective G-protein knockout
- Grants
- $4.7M
- 14 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 13
- 5 granted · 8 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Fast and Accurate Tools for Measuring Fluorescence in Living Cells | $582,394 | |
| Federal grant | Department of Health and Human Services · Phase I · A robust assay for detecting agonist bias in living cells. | $193,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | $227,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Live Cell Assays to Identify and Interrogate Stressed Neurons in Models of Neurodegenerative Disease. | $195,833 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Development of technologies to advance fast and accurate tools for measuring fluorescence in living cells, with emphasis on developing assays optimized for screening in neuronal cells and brain tissue | $210,309 | |
| Federal grant | Department of Health and Human Services · Phase I · I-Corps Proposal for Commercialization of Live Cell Assays to Identify and Interrogate Stressed Neurons in Models of Neurodegenerative Disease | $55,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A robust assay for detecting agonist bias in living cells. | $634,836 | |
| Federal grant | Department of Health and Human Services · Phase II · An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder | $221,097 | |
| Federal grant | Department of Health and Human Services · Phase II · A robust assay for detecting agonist bias in living cells. | $600,181 | |
| Federal grant | Department of Health and Human Services · Phase II · An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder | $482,109 | |
| Federal grant | Department of Health and Human Services · Phase II · An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder | $315,386 | |
| Federal grant | Department of Health and Human Services · Phase II · Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Live Cell Fluorescent Assays for SARS-CoV-2 protease activity and COVID-19 Drug Discovery | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Fluorescent Biosensors for measuring the signaling kinetics of GPCR ligands that activate G12/13 pathways. | $364,367 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3006 | REVERSAL THERAPEUTICS INC | — | — |
| 3007 | EARNANO, LLC | — | — |
| 3008 | SPEKCITON BIOSCIENCES LLC | — | — |
| 3009 | MONTANA MOLECULAR, LLC | — | — |
| 3010 | ARGOS VISION INC. | — | — |
| 3011 | BACSTITCH DNA INC. | — | — |
| 3012 | Aincobio LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Biosensors For Detecting Arrestin Signalinggranted
- GENETICALLY ENCODED FLUORESCENT SENSORS FOR DETECTING LIGAND BIAS AND INTRACELLULAR SIGNALING THROUGH cAMP PATHWAYSgranted
- Protease Biosensors And Methods Of Virus Detectionapplication
- GENETICALLY ENCODED FLUORESCENT SENSORS FOR DETECTING LIGAND BIAS AND INTRACELLULAR SIGNALING THROUGH cAMP PATHWAYSgranted
- Genetically Encoded Fluorescent Sensors for Detecting Intracellular Signalling Through Diacylglycerol Pathwaysgranted
- Genetically Encoded Fluorescent Sensors For Detecting Intracellular Signalling Through Diacylglycerol Pathwaysgranted
- Genetically Encoded Fluorescent Sensors For Detecting Ligand Bias And Intracellular Signaling Through Camp Pathwaysapplication
- Genetically Encoded Fluorescent Sensors For Detecting Intracellular Signalling Through Diacylglycerol Pathwaysapplication
- Protease Biosensors And Methods Of Virus Detectionapplication
- Protease Biosensors And Methods Of Virus Detectionapplication
- Biosensors For Detecting Arrestin Signalingapplication
- Biosensors for detecting arrestin signalingapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.